# Long-term clinical sequelae among Sudan ebolavirus disease survivors 2Â years post-infection: a matched cohort study.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12275283</article-id><article-id pub-id-type="pmid">40682158</article-id>
<article-id pub-id-type="publisher-id">4271</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04271-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Long-term clinical sequelae among Sudan ebolavirus disease survivors 2&#x000a0;years post-infection: a matched cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Muwonge</surname><given-names>Haruna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nasimiyu</surname><given-names>Carolyne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bakamutumaho</surname><given-names>Barnabas</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Elyanu</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Joloba</surname><given-names>Moses L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Situma</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schieffelin</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Gunn</surname><given-names>Bronwyn</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Shuangyi</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Breiman</surname><given-names>Robert F.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ssewanyana</surname><given-names>Isaac</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nabadda</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lutwama</surname><given-names>Julius</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tegen</surname><given-names>Yonas</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Muruta</surname><given-names>Allan</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kirenga</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Olaro</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Aceng</surname><given-names>Jane Ruth</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Bosa</surname><given-names>Henry Kyobe</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Njenga</surname><given-names>M. Kariuki</given-names></name><address><email>Mkariuki.njenga@wsu.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dmz0111</institution-id><institution-id institution-id-type="GRID">grid.11194.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0620 0548</institution-id><institution>Makerere University Medical School, </institution></institution-wrap>Kampala, Uganda </aff><aff id="Aff2"><label>2</label>Center for Research in Emerging Infectious Diseases-East and Central Africa, Washington State University Global Health-Kenya, Nairobi, Kenya </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04509n826</institution-id><institution-id institution-id-type="GRID">grid.415861.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1790 6116</institution-id><institution>Uganda Virus Research Institute, </institution></institution-wrap>Entebbe, Uganda </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01e6deg73</institution-id><institution-id institution-id-type="GRID">grid.423308.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0397 2008</institution-id><institution>Baylor College of Medicine Children Foundation-Uganda, </institution></institution-wrap>Kampala, Uganda </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vmvtb21</institution-id><institution-id institution-id-type="GRID">grid.265219.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2217 8588</institution-id><institution>West Africa Research Network of Infectious Disease, </institution><institution>Tulane University, </institution></institution-wrap>New Orleans, USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05dk0ce17</institution-id><institution-id institution-id-type="GRID">grid.30064.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 6568</institution-id><institution>Paul G. Allen School for Global Health, </institution><institution>Washington State University, </institution></institution-wrap>Pullman, USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03czfpz43</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7398</institution-id><institution>Emory University, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff8"><label>8</label>Uganda Central Public Health Laboratories, Kampala, Uganda </aff><aff id="Aff9"><label>9</label>Independent Global Health Consultant, Kampala, Uganda </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hy3gq97</institution-id><institution-id institution-id-type="GRID">grid.415705.2</institution-id><institution>Ministry of Health Uganda, </institution></institution-wrap>Kampala, Uganda </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>432</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par13">The long-term health effects of ebolavirus disease (EVD) caused by the Sudan ebolavirus (SUDV) strain remain poorly characterized. Here, we assessed the nature, frequency, and persistence of post-EVD clinical symptoms among SUDV survivors 2&#x000a0;years after infection by comparing them with matched community controls.</p></sec><sec><title>Methods</title><p id="Par14">The primary objective was determining the prevalence of clinical symptoms over the 24-month period. Using a prospective matched cohort approach, 87 laboratory-confirmed SUDV survivors from the 2022&#x02013;2023 Ugandan outbreak and 176 age-, sex- and village-matched controls were followed at 3, 9, 12, 15 and 24&#x000a0;months. Symptom data were collected through structured interviews and targeted clinical examinations. A secondary objective was investigating the duration of viral RNA shedding in semen and breast milk of survivors collected during follow-up, using the PCR test.</p></sec><sec><title>Results</title><p id="Par15">Of the 87 SUDV survivors, 57.5% reported significantly higher frequencies of clinical symptoms involving musculoskeletal (45.0%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), central nervous system (36.3%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), ophthalmologic (20%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and respiratory (10%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) systems than those observed among controls. The risk ratio of occurrence was highest for ophthalmologic (20% vs 3.4%, RR&#x02009;=&#x02009;5.9; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and central nervous systems symptoms (36.3% vs 6.8%, RR&#x02009;=&#x02009;5.3, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), and lowest for reproductive system (13.8% vs 8.5%; RR&#x02009;=&#x02009;1.6; <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.005). Importantly, 50% of the survivors reported persistent multi-systemic symptoms, including low back pain, hand and feet numbness, confusion, and diarrhoea that resulted in an inability to perform basic activities of living. Viral RNA was detected in semen for up to 210 post-infection (median&#x02009;=&#x02009;131&#x000a0;days, range: 111&#x02013;210&#x000a0;days) and in breast milk for up to 199&#x000a0;days (median&#x02009;=&#x02009;149&#x000a0;days, range: 111&#x02013;199&#x000a0;days).</p></sec><sec><title>Conclusions</title><p id="Par16">This study demonstrates that SUDV survivors develop long-term clinical sequelae characterized by persistent multi-systemic clinical symptoms. Detection of viral RNA in semen and breastmilk for up to 7&#x000a0;months post-infection suggests prolonged persistence, opening the possibility of latency and reactivation of the virus.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04271-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ebola virus disease</kwd><kwd>Sudan ebolavirus disease</kwd><kwd>Post-Ebola sequelae</kwd><kwd>Ebola survivors</kwd><kwd>Long-term health outcomes</kwd><kwd>Viral persistence</kwd><kwd>Reproductive health effects</kwd><kwd>Sub-Saharan Africa</kwd></kwd-group><funding-group><award-group><funding-source><institution>U.S. National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH)</institution></funding-source><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id><award-id>U01AI151799</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>U.S. National Institute of Allergy and Infectious Diseases/National Institutes of Health</institution></funding-source><award-id>R01AI175698</award-id><award-id>R01AI175698</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par38">Ebolavirus disease (EVD) is a severe, often fatal haemorrhagic fever in humans that is often caused by four ebolavirus strains: Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV), and Tai Forest (TAFV) viruses [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. While acute EVD has similar progression across the virus strains, with&#x02009;&#x0003e;&#x02009;50% of cases developing life-threatening complications such as hypotension and acute multi-organ failure, the case fatality rate (CFR) ranges from 75 to 90% for EBOV, 55 to 65% for SUDV, and 25 to 33% for BDBV [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Over the last 30&#x000a0;years, EBOV and SUDV have been the most prevalent strains, responsible for&#x02009;&#x0003e;&#x02009;70% of EVD epidemics, all originating from Africa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Recent studies, primarily in EBOV survivors, have described long-term EVD clinical sequelae characterized by sometimes severe and disabling musculoskeletal, neurological, psychological, ophthalmologic, and auditory symptoms that manifest from as early as 35&#x000a0;days after the acute EVD and can persist for years [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].
</p><p id="Par39">Following the 2014&#x02013;2016 West African EBOV epidemic, studies identified a wide spectrum of long-term clinical sequelae, primarily with musculoskeletal and ophthalmologic symptoms [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Sustained mental health impacts included post-traumatic stress disorder, depression, substance abuse, anxiety, psychosis, and suicidal ideation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Ocular symptoms were associated with high viral load and severe acute EVD disease characterized by hemorrhagic manifestations [<xref ref-type="bibr" rid="CR15">15</xref>]. More recent studies demonstrated that host-specific anti-EBOV immune responses correlated with clinical sequelae in part by predisposing individuals to virus persistence in immune-privileged sites, eliciting inflammatory reactions that yielded long-term clinical manifestations [<xref ref-type="bibr" rid="CR16">16</xref>]. To investigate EVD clinical sequelae in survivors of SUDV strain, we enrolled 87 survivors from the 2022 outbreak in Uganda [<xref ref-type="bibr" rid="CR17">17</xref>] shortly after discharge from Ebola treatment units (ETUs) and implemented long-term follow-up procedures. The outbreak, which started in September 2022, ended in January 2023, resulted in 142 confirmed SUDV cases, 55 deaths (CFR&#x02009;=&#x02009;38.7%).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and location</title><p id="Par40">We conducted a prospective matched cohort study starting from February 2023 following SUDV survivors of the September 22&#x02013;November 30, 2022, outbreak in Uganda. All 87 laboratory-confirmed SUDV survivors were consented and enrolled between February 1 and March 15, 2023, following discharge from Ebola Treatment Units (ETUs), a period regarded as 3&#x000a0;months post-infection. Using this timeline, subsequent follow-ups were conducted at 9, 12, 15 and 24&#x000a0;months post-infection, with the last 24-month follow-up completed on October 17, 2024. The study also enrolled 192 age-, sex- and location-matched community controls, drawn from the same or nearby villages as survivors. Controls were enrolled at a 2:1 ratio, with an additional 10% over-enrolment to account for potential seropositivity to SUDV. Seropositive controls (based on IgG reactivity to recombinant SUDV antigens) were subsequently excluded from analysis.</p><p id="Par41">Participant follow-up was embedded within an ongoing clinical and psychosocial support programme conducted by the MOH at three Uganda Ministry of Health (MOH) designated SUDV survivor clinics: Mubende Regional Referral Hospital, Kikandwa Health Centre III in Kassanda District, and Entebbe Regional Referral Hospital (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). These health facilities are in the 3 districts that served as epicentres of the outbreak: Mubende, Kassanda, and Kampala districts.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Spatial distribution of Sudan ebolavirus (SUDV) survivors and controls in Uganda<bold>.</bold> Map illustrating spatial distribution of SUDV survivors (red dots) and controls (green dots) across Mubende, Kassanda, Mityana, Wakiso, and Kampala districts. The study hospitals (blue crosses) include Mubende Regional Referral Hospital, Kikandwa Health Center III in Kassanda, and Entebbe Regional Referral Hospital in Wakiso. The insert map of Uganda shows the location of affected districts (orange shading)</p></caption><graphic xlink:href="12916_2025_4271_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Participant enrolment</title><p id="Par42">All 87-laboratory confirmed SUDV survivors were enrolled shortly after discharge from the Ebola Treatment Units (ETUs). Location, age, and sex-matched community controls were recruited from five villages where 86% of the survivors lived, with the number of controls proportional to the survivor population in each village. The matching criteria included location (same or nearby village), sex, and age (&#x000b1;&#x02009;1&#x000a0;year for children&#x02009;&#x0003c;&#x02009;5&#x000a0;years old,&#x02009;&#x000b1;&#x02009;2&#x000a0;years for participants 5&#x02013;40&#x000a0;years old, and&#x02009;&#x000b1;&#x02009;5&#x000a0;years for those&#x02009;&#x0003e;&#x02009;40&#x000a0;years). To minimize the chance of recruiting controls previously exposed to EVD, persons living in the same households with survivors, having a history of EVD exposure or fever between September and November 2022 were excluded.</p></sec><sec id="Sec5"><title>Clinical data collection and sampling</title><p id="Par43">Data were collected at enrolment and during follow-up visits using structured questionnaires, medical file abstraction, and physical examinations. For survivors, detailed information was gathered regarding their EVD illness, including clinical presentation, management, past medical history, known EVD exposure risk factors, persistent symptoms after discharge from the ETUs, and reproductive health history. Follow-up visits focused on updating the participants&#x02019; current health status, capturing new symptoms, hospitalizations, exacerbations of existing conditions, and changes in sexual health. The questionnaires systematically collected symptom information, categorized by body system as summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Symptom information collected during study visits, aggregated by body systems</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Body system</th><th align="left">Symptoms</th></tr></thead><tbody><tr><td align="left">General</td><td align="left">Fever, headache, fatigue, weakness, anorexia, weight loss, rash</td></tr><tr><td align="left">Musculoskeletal</td><td align="left">Joint pain, limb numbness, muscular pain, back pain, joint swelling</td></tr><tr><td align="left">Gastro-intestinal</td><td align="left">Abdominal pain, diarrhoea, vomiting, nausea, difficulty swallowing</td></tr><tr><td align="left">Respiratory</td><td align="left">Sore throat, difficulty breathing, chest pain, cough</td></tr><tr><td align="left">Ophthalmological</td><td align="left">Blurry vision, eye pain, watery eyes, vision loss, dry eyes</td></tr><tr><td align="left">Reproductive</td><td align="left">Reduced libido, testicular pain, erectile dysfunction, menstrual period change</td></tr><tr><td align="left">Central nervous system (CNS)</td><td align="left">Memory loss, depression, confusion, difficulty in sleeping</td></tr><tr><td align="left">Ear, nose, throat (ENT)</td><td align="left">Tinnitus, hearing loss</td></tr></tbody></table></table-wrap></p><p id="Par44">Additional information regarding clinical signs, medical complications, laboratory test results, imaging findings, and treatments administered during ETU admission was abstracted from health records. Questionnaires were administered by trained study nurses, while additional targeted physical examinations were performed by a trained medical officer using the standard clinical methodology [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par45">Venous blood was collected from controls, serum harvested, and transported to Uganda Central Public Health Laboratory to test for the presence of anti-SUDV antibodies and thus expulsion from the control group. From pregnant women, placental blood, amniotic fluid, and breast milk were collected, while baby tears and eye swabs were collected at delivery.</p></sec><sec id="Sec6"><title>Collection and testing semen and breast milk for viral RNA</title><p id="Par46">During each visit, eligible adult male survivors provided semen while lactating females provided breast milk samples through self-expression to be tested for viral RNA. Specimen collection containers and instructions were provided by a trained Ministry of Health team involved in the psychosocial follow-up program. The specimens were triple packaged in accordance with international standards, refrigerated and transported to either the EVD mobile laboratory at Mubende Regional Referral Hospital or the enhanced biosafety level-2 laboratory at the Uganda Virus Research Institute (UVRI). At the laboratory, samples were placed into a negative pressure isolating glovebox and chemically inactivated using a mixture of virus lysis buffer and ethanol according to the manufacturer&#x02019;s instructions (QIAmp viral RNA kit, Qiagen, Germany). Viral RNA was extracted from a 140-&#x000b5;l sample using the QIAmp viral RNA kit (Qiagen, Germany) followed by amplification cycling using the BioPerfectus ebolavirus real-time PCR kit (Jiangsu BioPerfectus Technologies, Taizhou, China) that detects both ebolavirus Zaire (EBOV) and SUDV strains.</p></sec><sec id="Sec7"><title>Screening sera from control participants for SUDV exposure</title><p id="Par47">Sera samples collected from the 192 controls were assayed for IgG reactivity to recombinant SUDV glycoprotein (GP) and nucleoprotein (NP). Recombinant SUDV GP (IBT Bioservices, Cat# 0502-015) and NP (Sino Biologics, Cat# 40444-V07E1) were individually coupled to MagPlex (Luminex) magnetic beads with distinct fluorescent properties. Serum samples were diluted 100-, 500- and 1000-fold and incubated with the antigen-coated beads for 2&#x000a0;h at room temperature at 900 RPM. After washing, the beads were incubated with 0.65&#x000a0;&#x000b5;g/ml of PE-labelled secondary antibodies to detect IgG (total IgG, Southern Biotech, Cat# 2040-09) and analysed on IntelliFLEX SE-DR instrument (Luminex). Seropositivity threshold was determined using sera from 24 presumed SUDV-na&#x000ef;ve controls (16 regional controls from Kenya and 8 controls from USA). For each antigen, we evaluated whether the data met the assumptions of normality. For the total IgG response to SUDV GP, the data followed a normal distribution as confirmed by the Shapiro&#x02013;Wilk test. For the NP data, one outlier was identified using the Robust Regression and Outlier Removal (ROUT) method. After removing the outlier, the remaining samples followed a normal distribution pattern.</p><p id="Par48">To minimize variability associated with a small sample size and maintain a conservative threshold, the seropositivity cut-off was calculated as mean plus five standard deviations (mean&#x02009;+&#x02009;5&#x02009;&#x000d7;&#x02009;SD) at each dilution level [<xref ref-type="bibr" rid="CR19">19</xref>]. Control participants were classified seropositive if their mean fluorescence index exceeded that of SUDV GP at all three dilutions or at both the 500- and 1000-fold dilutions. Seropositive controls were excluded from the study.</p></sec><sec id="Sec8"><title>Data analysis</title><p id="Par49">Clinical sequalae data cleaning and analysis were performed using R statistical software version 4.2.3. Descriptive analysis was conducted for categorical and numerical data and presented as frequencies, proportions, means and medians. Pearson&#x02019;s chi-square test or Fisher&#x02019;s exact test (where appropriate) was used to assess differences in symptom prevalence and other categorical variables between survivors and controls. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to compare the likelihood of developing clinical sequelae among survivors relative to controls. For the current analysis, symptom prevalence was calculated based on data collected at the final follow-up visit, 24&#x000a0;months post-infection. These frequencies reflect symptoms present at that specific time point and do not represent cumulative prevalence across earlier visits. This approach was applied to both aggregated body system symptoms and specific symptom categories. For numerical variables, Student&#x02019;s t-test or Mann&#x02013;Whitney U test was used depending on data distribution, with statistical significance set at <italic>p</italic>&#x02009;&#x02264;&#x02009;0.05. To understand the evolution of clinical sequelae over time, a temporal analysis was conducted, and the trends presented in the form of a heat map.</p><p id="Par50">To assess the duration of viral RNA shedding in semen and breastmilk specimens, we recorded the number of days post-infection that participants remained PCR positive. The endpoint was defined as the last PCR positive result that was followed by two consecutive PCR negative results during follow-up.</p></sec><sec id="Sec9"><title>Ethical considerations
</title><p id="Par51">The study protocol was reviewed and approved by the School of Biomedical Sciences Research Ethics Committee at Makerere University (approval # SBS-2022-243) and the Uganda National Council of Science and Technology (approval # HS2618ES). Reliance was provided by Washington State University. Additional administrative approvals were sought from the Ministry of Health Uganda and the study health facilities. Written informed consents were obtained from all study participants. Those who declined were excluded from the study.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Sociodemographic characteristics of Uganda SUDV survivors</title><p id="Par52">The mean age of survivors was 31 (&#x000b1;&#x02009;14) years while that of controls was 30 (&#x000b1;&#x02009;13) years (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). There was no significant difference in education level, occupation, or underlying conditions between survivors and controls.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Sociodemographic characteristics of SUDV survivors and controls at time of enrolment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">SUDV survivors, <bold><italic>N</italic></bold>&#x02009;=&#x02009;87<break/><italic>n</italic> (%)</th><th align="left">Controls, <bold><italic>N</italic></bold>&#x02009;=&#x02009;176<break/><italic>n</italic> (%)</th><th align="left"><bold><italic>p</italic></bold>-values</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left" rowspan="2">0.7</td></tr><tr><td align="left">&#x02003;Male</td><td align="left">56 (64.4)</td><td align="left">109 (62)</td></tr><tr><td align="left">Age</td><td align="left"/><td align="left"/><td align="left" rowspan="3">&#x02009;&#x0003e;&#x02009;0.9</td></tr><tr><td align="left">&#x02003;Mean (SD)</td><td align="left">31 (14)</td><td align="left">30 (13)</td></tr><tr><td align="left">&#x02003;Median (IQR)</td><td align="left">30 (23,38)</td><td align="left">29 (23,38)</td></tr><tr><td align="left">Age groups</td><td align="left"/><td align="left"/><td align="left" rowspan="7">&#x02009;&#x0003e;&#x02009;0.9</td></tr><tr><td align="left">&#x02003;0&#x02013;9</td><td align="left">6 (6.9)</td><td align="left">14 (8.0)</td></tr><tr><td align="left">&#x02003;10&#x02013;19</td><td align="left">11 (12.6)</td><td align="left">19 (11)</td></tr><tr><td align="left">&#x02003;20&#x02013;29</td><td align="left">30 (34.5)</td><td align="left">60 (34)</td></tr><tr><td align="left">&#x02003;30&#x02013;39</td><td align="left">25 (28.7)</td><td align="left">50 (28)</td></tr><tr><td align="left">&#x02003;40&#x02013;49</td><td align="left">10 (11.5)</td><td align="left">19 (11)</td></tr><tr><td align="left">&#x02003;50&#x02009;+&#x02009;</td><td align="left">5 (5.7)</td><td align="left">14 (8.0)</td></tr><tr><td align="left">Level of education</td><td align="left"/><td align="left"/><td align="left" rowspan="5">&#x02009;&#x0003e;&#x02009;0.9</td></tr><tr><td align="left">&#x02003;None</td><td align="left">45 (51.8)</td><td align="left">82 (46.6)</td></tr><tr><td align="left">&#x02003;Primary</td><td align="left">16 (18.4)</td><td align="left">39 (22.2)</td></tr><tr><td align="left">&#x02003;Secondary</td><td align="left">15 (17.2)</td><td align="left">33 (18.7)</td></tr><tr><td align="left">&#x02003;Tertiary</td><td align="left">11 (12.6)</td><td align="left">22 (12.5)</td></tr><tr><td align="left">Main occupation</td><td align="left"/><td align="left"/><td align="left" rowspan="7">0.3</td></tr><tr><td align="left">&#x02003;Farmer</td><td align="left">31 (48.2)</td><td align="left">66 (37.5)</td></tr><tr><td align="left">&#x02003;None</td><td align="left">17 (19.5)</td><td align="left">32 (18.2)</td></tr><tr><td align="left">&#x02003;Healthcare worker</td><td align="left">8 (9.2)</td><td align="left">3 (1.7)</td></tr><tr><td align="left">&#x02003;Skilled labour<sup>a</sup></td><td align="left">7 (8.0)</td><td align="left">17 (9.7)</td></tr><tr><td align="left">&#x02003;Unskilled labour</td><td align="left">5 (5.7)</td><td align="left">4 (2.3)</td></tr><tr><td align="left">&#x02003;Other<sup>b</sup></td><td align="left">19 (21.8)</td><td align="left">54 (30.7)</td></tr><tr><td align="left">Chronic conditions</td><td align="left"/><td align="left"/><td align="left" rowspan="5">NA</td></tr><tr><td align="left">&#x02003;Hypertension</td><td align="left">6 (6.9)</td><td align="left">7 (3.6)</td></tr><tr><td align="left">&#x02003;HIV</td><td align="left">5 (5.7)</td><td align="left">6 (3.4)</td></tr><tr><td align="left">&#x02003;Diabetes</td><td align="left">2 (2.3)</td><td align="left">1 (0.5)</td></tr><tr><td align="left">&#x02003;Others</td><td align="left">6 (6.9)</td><td align="left">2 (1.1)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Except healthcare workers</p><p><sup>b</sup>Businessmen, hairdressers, chefs, carpenters, shop attendants</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Comparing systemic clinical symptoms among survivors and controls</title><p id="Par53">Overall, 57.5% (50 of 87) of SUDV survivors developed at least one clinical symptom during the follow-up period, when compared to 32.4% of controls (RR&#x02009;=&#x02009;1.8, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). When compared to controls, there was a significantly higher frequency of clinical symptoms among survivors for the musculoskeletal, central nervous system (CNS), ophthalmological, reproductive, respiratory, and gastrointestinal systems (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The risk ratios were highest for ophthalmologic and CNS symptoms among SUDV survivors: 5.9 (20% vs 3.4%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and 5.3 (36.3% vs 6.8%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), respectively, when compared to controls, and lowest in reproductive system symptoms was&#x02009;&#x0003c;&#x02009;2 (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Frequency of systemic clinical symptoms among SUDV survivors and controls at 24&#x000a0;months post-infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Body system</th><th align="left">Survivors, <italic>N</italic>&#x02009;=&#x02009;80<break/><italic>n</italic> (%)</th><th align="left">Controls, <italic>N</italic>&#x02009;=&#x02009;176<break/><italic>n</italic> (%)</th><th align="left">Risk ratio</th><th align="left">95% CI</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Overall</td><td align="left">46 (57.5)</td><td align="left">57 (32.4)</td><td align="left">1.8</td><td align="left">1.3, 2.4</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Musculoskeletal<sup>a</sup></td><td align="left">36 (45.0)</td><td align="left">25 (14.0)</td><td align="left">3.2</td><td align="left">2.1,4.9</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">General<sup>b</sup></td><td align="left">31 (38.8)</td><td align="left">34 (19.0)</td><td align="left">2.0</td><td align="left">1.3,3.0</td><td align="left">0.002</td></tr><tr><td align="left">Central nervous system<sup>c</sup></td><td align="left">29 (36.3)</td><td align="left">12 (6.8)</td><td align="left">5.3</td><td align="left">2.9,9.9</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Ophthalmological<sup>d</sup></td><td align="left">16 (20.0)</td><td align="left">6 (3.4)</td><td align="left">5.9</td><td align="left">2.4,14.4</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Reproductive<sup>e</sup></td><td align="left">11 (13.8)</td><td align="left">15 (8.5)</td><td align="left">1.6</td><td align="left">0.8,3.4</td><td align="left">0.026</td></tr><tr><td align="left">Respiratory<sup>f</sup></td><td align="left">8 (10.0)</td><td align="left">4 (2.3)</td><td align="left">4.4</td><td align="left">1.4,14.2</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Gastro-intestinal<sup>g</sup></td><td align="left">12 (15.0)</td><td align="left">7 (4.0)</td><td align="left">3.8</td><td align="left">1.5,9.2</td><td align="left">0.011</td></tr><tr><td align="left">Auditory<sup>h</sup></td><td align="left">3 (3.8)</td><td align="left">1 (0.6)</td><td align="left">6.6</td><td align="left">0.7,62.5</td><td align="left">0.092</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Muscle pain, joint pain, hand and feet numbness, lower back pain</p><p><sup>b</sup>Fever, fatigue, general body weakness, headache, weight loss, anorexia</p><p><sup>c</sup>Stiff neck, confusion, seizures, difficulty sleeping</p><p><sup>d</sup>Eye pain, dry eyes, watery eyes, blurry vision, vision loss</p><p><sup>e</sup>Irregular menstrual periods, erectile dysfunction, testicular pain, reduced libido</p><p><sup>f</sup>Difficulty breathing, chest pain, sore throat, depression</p><p><sup>g</sup>Abdominal pain, diarrhoea, nausea, vomiting</p><p><sup>h</sup>Hearing loss, buzzing sound in the ears</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Heat map showing symptom reporting among Sudan ebolavirus (SUDV) survivors over 24&#x000a0;months. This heat map illustrates the proportion of SUDV survivors reporting symptoms across different body systems at 3, 9, 12, 15, and 24&#x000a0;months post-infection. The colour gradient represents the symptom reporting rate (%), with red shades indicating higher prevalence (&#x0003e;&#x02009;50%) and green shades representing lower prevalence (&#x0003c;&#x02009;10%)</p></caption><graphic xlink:href="12916_2025_4271_Fig2_HTML" id="MO2"/></fig></p><p id="Par54">Overall, symptoms related to the musculoskeletal (45%) system were the most frequent symptoms observed among survivors, although these were detected more often in controls as well (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The number of survivors reporting clinical symptoms was stable over time: 55.2% (48 of 87) at enrolment and 57.5% (46 of 80) at 2&#x000a0;years post-infection. Clinical symptoms associated with general, musculoskeletal, CNS, and ophthalmological systems were sustained at comparable proportions at 3, 9, 12, and 24&#x000a0;months post-infection (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p></sec><sec id="Sec13"><title>Characterization of specific clinical symptoms</title><p id="Par55">As shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, the most frequent specific clinical symptoms reported by survivors were memory loss (35.0%), lower back pain (31.3%), hand and feet numbness (25.0%), and headache (21.3%). When compared to controls, the risk ratios of reported memory loss, blurry vision, depression, and sore throat were&#x02009;&#x0003e;&#x02009;5.5 among survivors, and for reporting joint pains, weakness, eye pain, chest pain, hand and feet numbness, headache, and muscular pain, the risk ratios were between 3 and 5.5 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Frequency and relative risk of specific clinical symptoms reported by SUDV survivors and controls at 24&#x000a0;months post-infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Symptoms</th><th align="left">Survivors, <italic>N</italic>&#x02009;=&#x02009;80<break/><italic>n</italic> (%)</th><th align="left">Controls, <italic>N</italic>&#x02009;=&#x02009;176<break/><italic>n</italic> (%)</th><th align="left">Risk ratio</th><th align="left">95% CI</th><th align="left"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left">Memory loss</td><td align="left">28 (35.0)</td><td align="left">9 (5.1)</td><td align="left">6.8</td><td align="left">3.4,13.8</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Lower back pain</td><td align="left">25 (31.3)</td><td align="left">19 (10.8)</td><td align="left">2.9</td><td align="left">1.7,4.9</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Hand feet Numbness</td><td align="left">20 (25.0)</td><td align="left">13 (7.4)</td><td align="left">3.4</td><td align="left">1.8,6.5</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Headache</td><td align="left">17 (21.3)</td><td align="left">11 (6.3)</td><td align="left">3.4</td><td align="left">1.7,6.9</td><td align="left">0.001</td></tr><tr><td align="left">Weakness</td><td align="left">16 (20.0)</td><td align="left">7 (4)</td><td align="left">5.0</td><td align="left">2.2,11.7</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Joint pain</td><td align="left">12 (15.0)</td><td align="left">5 (2.8)</td><td align="left">5.3</td><td align="left">1.9,14.5</td><td align="left">0.001</td></tr><tr><td align="left">Fatigue</td><td align="left">10 (12.5)</td><td align="left">15 (8.5)</td><td align="left">1.5</td><td align="left">0.7,3.1</td><td align="left">0.365</td></tr><tr><td align="left">Blurry vision</td><td align="left">9 (11.3)</td><td align="left">3 (1.7)</td><td align="left">6.6</td><td align="left">1.8,23.7</td><td align="left">0.002</td></tr><tr><td align="left">Chest pain</td><td align="left">7 (8.8)</td><td align="left">4 (2.3)</td><td align="left">3.9</td><td align="left">1.2,12.2</td><td align="left">0.039</td></tr><tr><td align="left">Eye pain</td><td align="left">6 (7.5)</td><td align="left">3 (1.7)</td><td align="left">4.4</td><td align="left">1.1,17.2</td><td align="left">0.029</td></tr><tr><td align="left">Muscular pain</td><td align="left">6 (7.5)</td><td align="left">4 (2.3)</td><td align="left">3.3</td><td align="left">1.0,11.4</td><td align="left">0.075</td></tr><tr><td align="left">Depression</td><td align="left">5 (6.3)</td><td align="left">2 (1.1)</td><td align="left">5.5</td><td align="left">1.1,27.8</td><td align="left">0.032</td></tr><tr><td align="left">Weight loss</td><td align="left">4 (5.0)</td><td align="left">5 (2.8)</td><td align="left">1.8</td><td align="left">0.5,6.4</td><td align="left">0.467</td></tr><tr><td align="left">Anorexia</td><td align="left">3 (3.8)</td><td align="left">4 (2.3)</td><td align="left">1.7</td><td align="left">0.4,7.2</td><td align="left">0.681</td></tr><tr><td align="left">Sore throat</td><td align="left">3 (3.8)</td><td align="left">1 (0.6)</td><td align="left">6.6</td><td align="left">0.7,62.5</td><td align="left">0.092</td></tr></tbody></table></table-wrap></p><p id="Par56">Of the 46 (57.5%) survivors that reported at least one symptom at 2&#x000a0;years post-infection time point, 60.9% reported more than three symptoms, 26.1% reported 2&#x02013;3 symptoms, and 13% reported one symptom. Five of the 46 (10.9%) symptomatic participants reported symptoms that interfered with their daily activities, including hand and feet numbness, lower back pain, reduced libido, confusion, and diarrhoea. Overall, 50% (40/80) of all SUDV survivors reported persistent multiple (&#x0003e;&#x02009;2) symptoms over the 2-year follow-up period.</p></sec><sec id="Sec14"><title>Age and gender differences in symptom presentation</title><p id="Par57">SUDV survivor demographics played a significant role in long-term clinical sequelae. Older survivors reported joint pain significantly more frequently than younger age groups (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;16.87, <italic>p</italic>&#x02009;=&#x02009;0.005). Although other symptoms such as memory loss, lower back pain, and hand/feet numbness were reported across age groups, these differences were not statistically significant. Symptom distribution across different age groups is shown in Additional file 1: Table S1.</p><p id="Par58">Gender also influenced symptom presentation among survivors. Female survivors more commonly reported fatigue (RR&#x02009;=&#x02009;0.24, <italic>p</italic>&#x02009;=&#x02009;0.018), weakness (RR&#x02009;=&#x02009;0.34, <italic>p</italic>&#x02009;=&#x02009;0.015), headache (RR&#x02009;=&#x02009;0.40, <italic>p</italic>&#x02009;=&#x02009;0.029), and depression (RR&#x02009;=&#x02009;0.14, <italic>p</italic>&#x02009;=&#x02009;0.036) than their male counterparts. These differences highlight potential sex-specific vulnerabilities in post-SUDV sequelae. Additional file 2: Table S2 presents the frequency and relative risk of specific clinical symptoms stratified by gender among SUDV survivors.</p></sec><sec id="Sec15"><title>Detection of viral RNA in semen and breastmilk for over 6&#x000a0;months</title><p id="Par59">Of 47 male SUDV survivors aged&#x02009;&#x02265;&#x02009;16&#x000a0;years and eligible for semen testing, 33 (70.2%) consented and were tested at enrolment, where SUDV RNA was detected in 16 (48.5%) by PCR. Four lactating mothers consented to breastmilk testing, and all were PCR positive for SUDV RNA at enrolment. Sixteen (<italic>N</italic>&#x02009;=&#x02009;16) viral RNA positive men and the 4 lactating mothers agreed to subsequent testing during monthly psychosocial follow-up visits in accordance with World Health Organization guidelines until two consecutive samples were PCR negative. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, the median duration for semen positivity was 131&#x000a0;days, with the longest duration being 210&#x000a0;days. For breast milk, the median duration of PCR positivity was 149&#x000a0;days, with the longest duration of positivity being 199&#x000a0;days.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Duration of Sudan ebolavirus (SUDV) RNA detection in semen and breast milk samples. This figure illustrates the number of days that semen (orange, <italic>n</italic>&#x02009;=&#x02009;16) and breast milk (blue, <italic>n</italic>&#x02009;=&#x02009;4) samples tested positive for SUDV RNA by PCR. Each dot represents an individual participant</p></caption><graphic xlink:href="12916_2025_4271_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec16"><title>Survivor pregnancy outcomes</title><p id="Par60">Four out of five (80%) survivors who became pregnant during the study period delivered babies at term without complications or abnormalities. One (20%) survivor reported spontaneous first-trimester abortion at 12&#x000a0;weeks&#x02019; gestation. All post-partum samples, including amniotic fluid, placental cord blood, breastmilk, baby tears and conjunctival swabs, tested negative for SUDV RNA by PCR.</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par61">This study characterized, for the first time, the type and prevalence of clinical symptoms observed during long-term EVD sequelae associated with SUDV, in a case-control approach that enhanced interpretation of findings. At 2&#x000a0;years, statistically significant symptom-specific risk ratios ranged between 2.9 and 6.8 when compared to controls. Memory loss, lower back pain, hand and feet numbness, and headache were the most prevalent symptoms among survivors. Importantly, symptoms were sustained at comparable levels across the 2-year follow-up period, consistent with studies in EBOV survivors which reported sustained clinical symptoms over the 4&#x000a0;years after infection [<xref ref-type="bibr" rid="CR5">5</xref>]. Over longer periods of time, studies suggest that symptoms appear to resolve for EBOV and BDBV survivors; several studies note higher prevalence of clinical symptoms during convalescent periods when compared to 5&#x000a0;years later [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] This finding remains to be demonstrated in SUDV survivors. In our study, a substantial proportion of survivors reported debilitating symptoms, such as lower back pain, hand and feet numbness, reduced libido, confusion, and diarrhoea that interfered with wellness and daily living, such as working in subsistence farming, cooking, and house cleaning.</p><p id="Par62">Some of the high-risk symptoms reported among SUDV survivors were consistent with those reported among EBOV strain survivors, including high prevalence of musculoskeletal and ophthalmological clinical symptoms [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. We found 26.5% and 14.5% of SUDV survivors reporting arthralgia and muscular pain, respectively, compared to 18&#x02013;87% and 43% among EBOV survivors [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. However, the prevalence of some clinical symptoms was different between EBOV and SUDV survivors. For example, while ear, nose, and throat (ENT) symptoms were among the least prevalent (4.8%) in SUDV survivors, a&#x02009;&#x0003e;&#x02009;fivefold (27%) higher proportion of EBOV survivors reported tinnitus and hearing loss [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. On the other hand, we found a higher prevalence of CNS symptoms including memory loss (35%), hand and feet numbness (25%), and depression (5%) than those reported for EBOV survivors (12% memory loss, 12% hand numbness, 16% feet numbness) [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Whether these differences reflect different viral pathogenesis pathways or differential host immune responses to the virus strains merits further investigations.</p><p id="Par63">Although the pathophysiological mechanisms for long-term clinical sequelae following EVD remain poorly understood, they are speculated to involve either (i) direct virus pathways by persisting in tissues such as CNS and eye [<xref ref-type="bibr" rid="CR28">28</xref>], (ii) host immune activation leading to inflammation and tissue damage or autoantibodies-mediated pathophysiology [<xref ref-type="bibr" rid="CR29">29</xref>], or (iii) both pathways. The ebolavirus ability to evade the immune system and establish latency has been demonstrated [<xref ref-type="bibr" rid="CR30">30</xref>] and an association between higher viral load during acute EVD and the development of certain sequelae is described [<xref ref-type="bibr" rid="CR31">31</xref>]; the latter suggesting that the initial severity of the infection may influence the likelihood and severity of chronic EVD sequelae.</p><p id="Par64">In our study, there was evidence of persistent virus infection in male and lactating female SUDV survivors, indicated by detection of SUDV RNA in semen and breastmilk for an average of 5&#x000a0;months, and for some men up to 2&#x000a0;years post-infection in semen. Importantly, in two males SUDV RNA was detected in semen 8&#x000a0;months after negative results on consecutive samplings, suggesting latency and reactivation of the virus. Similar findings have been reported for EBOV, documenting viral RNA presence for up to 18&#x000a0;months after infection [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Detection of SUDV RNA in breastmilk signifies a notable risk for vertical transmission from mother to child, while virus in semen confirms the risk of sexual transmission as reported in some studies [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. Despite the paucity of documented secondary transmission through these pathways, the potential warrants implementation of informed breastfeeding guidelines for SUDV survivors, and safe sex training for ebolavirus-discordant couples. Breastfeeding guidelines carefully balance the benefits of breastfeeding with the risks of ebolavirus transmission, optimizing the safety of both survivors and their infants while drawing on the latest research findings to provide optimal evidence-based recommendations [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par65">SUDV survivor demographics played a significant role in long-term clinical sequelae, with older survivors reporting joint pain significantly more frequently (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;16.87, <italic>p</italic>&#x02009;=&#x02009;0.005), while female survivors more commonly reported fatigue (RR&#x02009;=&#x02009;0.24, <italic>p</italic>&#x02009;=&#x02009;0.018), weakness (RR&#x02009;=&#x02009;0.34, <italic>p</italic>&#x02009;=&#x02009;0.015), headache (RR&#x02009;=&#x02009;0.40, <italic>p</italic>&#x02009;=&#x02009;0.029), and depression (RR&#x02009;=&#x02009;0.14, <italic>p</italic>&#x02009;=&#x02009;0.036). These findings mirror those observed in EBOV survivors [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], underscoring distinct age- and gender-related patterns of post-EVD symptomatology. Taken together, these results highlight the need for tailored care strategies that address the unique needs of different demographic groups, as well as further research to refine management guidelines for EVD survivors.</p><p id="Par66">While we found that 4 of the 5 (80%) female survivors who became pregnant after infection had normal birth outcomes, and that both maternal and foetal postpartum tissues were negative for viral RNA, the numbers are too small to conclude minimal risk of vertical transmission. However, studies among a larger cohort of EBOV survivors reported adverse pregnancy outcomes, including high rates of spontaneous abortion and stillbirths, that were reported among EBOV survivors [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. These findings suggest continued follow-up studies among pregnant EVD survivors before the development of policy guidelines regarding the impact of EVD on pregnancy outcomes.</p><p id="Par67">Our study had some limitations. First, the small sample size and limited sampling timepoints precluded our ability to identify significant trends in sequelae. Second, the study was observational, with self-reporting as the primary source of clinical sequelae data, thus limiting causal inferences. Third, we did not collect detailed medical history or baseline symptom profiles for survivors prior to their acute SUDV infection, which limited our ability to adjust for pre-existing conditions as potential confounders in our comparisons with controls. This may have introduced some degree of selection bias in interpreting symptom differences. However, follow-up examination of survivors reporting certain symptoms by a trained medical officer strengthened the interpretation of the findings, as did the similarly collected data from matched controls. Data collected from future outbreaks would be helpful, as will continued follow-up of the cohort to continue characterizing long-term health impacts of SUDV.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par68">Our study demonstrates that SUDV survivors, much like EBOV survivors, develop long-term clinical sequelae characterized by persistent multi-systemic debilitating clinical symptoms. Our virology findings confirm SUDV persistence in survivors, with potential for latency and reactivation that may be a source of future human-to-human transmission and outbreaks.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4271_MOESM1_ESM.docx"><caption><p>Additional File 1: Table S1: Distribution of specific symptoms by age group among SUDV survivors.&#x000a0;This table presents the frequency of each clinical symptom stratified by age group. Statistical comparisons were made using chi-square tests to assess associations between symptom occurrence and age category.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4271_MOESM2_ESM.docx"><caption><p>Additional File 2: Table S2: Frequency and relative risk of specific clinical symptoms by gender among SUDV survivors.&#x000a0;This table details the number of male and female survivors reporting each symptom and presents the associated risk ratios, 95% confidence intervals, and <italic>p</italic>-values.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BDBV</term><def><p id="Par17">Bundibugyo ebolavirus</p></def></def-item><def-item><term>CFR</term><def><p id="Par18">Case fatality rate</p></def></def-item><def-item><term>CI</term><def><p id="Par19">Confidence interval</p></def></def-item><def-item><term>CNS</term><def><p id="Par20">Central nervous system</p></def></def-item><def-item><term>EBOV</term><def><p id="Par21">Ebola virus (Zaire strain)</p></def></def-item><def-item><term>ENT</term><def><p id="Par22">Ear, nose, and throat</p></def></def-item><def-item><term>ETU</term><def><p id="Par23">Ebola treatment unit</p></def></def-item><def-item><term>EVD</term><def><p id="Par24">Ebolavirus disease</p></def></def-item><def-item><term>GP</term><def><p id="Par25">Glycoprotein</p></def></def-item><def-item><term>IgG</term><def><p id="Par26">Immunoglobulin G</p></def></def-item><def-item><term>IQR</term><def><p id="Par27">Interquartile range</p></def></def-item><def-item><term>MOH</term><def><p id="Par28">Ministry of Health</p></def></def-item><def-item><term>NP</term><def><p id="Par29">Nucleoprotein</p></def></def-item><def-item><term>PCR</term><def><p id="Par30">Polymerase chain reaction</p></def></def-item><def-item><term>PE</term><def><p id="Par31">Phycoerythrin</p></def></def-item><def-item><term>RNA</term><def><p id="Par32">Ribo-nucleic acid</p></def></def-item><def-item><term>RR</term><def><p id="Par33">Risk ratio</p></def></def-item><def-item><term>SD</term><def><p id="Par34">Standard deviation</p></def></def-item><def-item><term>SUDV</term><def><p id="Par35">Sudan ebolavirus</p></def></def-item><def-item><term>TAFV</term><def><p id="Par36">Tai Forest ebolavirus</p></def></def-item><def-item><term>UVRI</term><def><p id="Par37">Uganda Virus Research Institute</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Change history</bold></p><p>9/10/2025</p><p>The original article has been updated to add an Acknowledgement.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We acknowledge support from the Uganda Ministry of Health, the Baylor-Uganda, Makerere University Lung Institute, Makerere University Biomedical Research Center, Uganda National Health Research Organization, and all staff at the 3 SUDV survivor clinics for their dedication and contributions to this research. We appreciate support from Alex Tumusiime and Jackson Kyondo at Uganda Virus Research Institute for assistance in sample collection and testing. We acknowledge the US Centers for Disease Control and Prevention (CDC) and USAID for their funding support to set up and implement the Ebola survivor program.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>HM, CN, BB, MKN, JS, RFB, SS, BG, conceptualizing, data collection, writing. MN, MS, EB, data collection. DO, RO, EO, data analysis. SB, PE, IS, data collection, revising. EMO, IN, MN, MS, EB,MLJ, SN, JL, YT, AM, BK, CO, JRA, HKB, reviewing, revising. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the U.S. National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), under grant number U01AI151799, through the Centre for Research in Emerging Infectious Diseases&#x02013;East and Central Africa (CREID-ECA). Bronwyn Gunn and John Schieffelin were supported in part by NIH/NIAID R01AI175698.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and/or analyzed during the current study are not publicly available due to participant confidentiality and institutional data protection policies, but are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par69">The study protocol was reviewed and approved by the School of Biomedical Sciences Research Ethics Committee at Makerere University (Approval #SBS-2022-243) and the Uganda National Council of Science and Technology (Approval #HS2618ES). Additional administrative approvals were obtained from the Uganda Ministry of Health and participating health facilities. Written informed consent was obtained from all participants prior to enrollment.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par70">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par71">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>ST</given-names></name><name><surname>Crozier</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Hewlett</surname><given-names>A</given-names></name><name><surname>Kraft</surname><given-names>CS</given-names></name><name><surname>Vega</surname><given-names>M-AdL</given-names></name><etal/></person-group><article-title>Ebola virus disease</article-title><source>Nat Rev Dis&#x000a0;Primers</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-0147-3</pub-id><?supplied-pmid 32080199?><pub-id pub-id-type="pmid">32080199</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, Vega M-AdL, et al. Ebola virus disease. Nat Rev Dis&#x000a0;Primers. 2020;6(1):13.<pub-id pub-id-type="pmid">32080199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Geisbert</surname><given-names>TW</given-names></name></person-group><article-title>Ebola haemorrhagic fever</article-title><source>The Lancet</source><year>2011</year><volume>377</volume><issue>9768</issue><fpage>849</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60667-8</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Feldmann H, Geisbert TW. Ebola haemorrhagic fever. The Lancet. 2011;377(9768):849&#x02013;62.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Baize</surname><given-names>S</given-names></name><name><surname>Pannetier</surname><given-names>D</given-names></name><name><surname>Oestereich</surname><given-names>L</given-names></name><name><surname>Rieger</surname><given-names>T</given-names></name><name><surname>Koivogui</surname><given-names>L</given-names></name><name><surname>Magassouba</surname><given-names>NF</given-names></name><etal/></person-group><article-title>Emergence of Zaire Ebola Virus Disease in Guinea</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>15</issue><fpage>1418</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1404505</pub-id><?supplied-pmid 24738640?><pub-id pub-id-type="pmid">24738640</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba NF, et al. Emergence of Zaire Ebola Virus Disease in Guinea. N Engl J Med. 2014;371(15):1418&#x02013;25.<pub-id pub-id-type="pmid">24738640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Izudi</surname><given-names>J</given-names></name><name><surname>Bajunirwe</surname><given-names>F</given-names></name></person-group><article-title>Case fatality rate for Ebola disease, 1976&#x02013;2022: A meta-analysis of global data</article-title><source>J Infect Public Health</source><year>2024</year><volume>17</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2023.10.020</pub-id><?supplied-pmid 37992431?><pub-id pub-id-type="pmid">37992431</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976&#x02013;2022: A meta-analysis of global data. J Infect Public Health. 2024;17(1):25&#x02013;34.<pub-id pub-id-type="pmid">37992431</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Tozay</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Wohl</surname><given-names>DA</given-names></name><name><surname>Kilpatrick</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Reeves</surname><given-names>E</given-names></name><etal/></person-group><article-title>Long-term Complications of Ebola Virus Disease: Prevalence and Predictors of Major Symptoms and the Role of Inflammation</article-title><source>Clin Infect Diseases</source><year>2020</year><volume>71</volume><issue>7</issue><fpage>1749</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz1062</pub-id><pub-id pub-id-type="pmid">31693114</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tozay S, Fischer WA, Wohl DA, Kilpatrick K, Zou F, Reeves E, et al. Long-term Complications of Ebola Virus Disease: Prevalence and Predictors of Major Symptoms and the Role of Inflammation. Clin Infect Diseases. 2020;71(7):1749&#x02013;55.<pub-id pub-id-type="pmid">31693114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Sneller</surname><given-names>MC</given-names></name><name><surname>Reilly</surname><given-names>C</given-names></name><name><surname>Badio</surname><given-names>M</given-names></name><name><surname>Bishop</surname><given-names>RJ</given-names></name><name><surname>Eghrari</surname><given-names>AO</given-names></name><name><surname>Moses</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>A Longitudinal Study of Ebola Sequelae in Liberia</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>10</issue><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805435</pub-id><?supplied-pmid 30855742?><pub-id pub-id-type="pmid">30855742</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, et al. A Longitudinal Study of Ebola Sequelae in Liberia. N Engl J Med. 2019;380(10):924&#x02013;34.<pub-id pub-id-type="pmid">30855742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Mattia</surname><given-names>JG</given-names></name><name><surname>Vandy</surname><given-names>MJ</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Platt</surname><given-names>DE</given-names></name><name><surname>Dierberg</surname><given-names>K</given-names></name><name><surname>Bausch</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><issue>3</issue><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00489-2</pub-id><?supplied-pmid 26725449?><pub-id pub-id-type="pmid">26725449</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2016;16(3):331&#x02013;8.<pub-id pub-id-type="pmid">26725449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DV</given-names></name><name><surname>Kibuuka</surname><given-names>H</given-names></name><name><surname>Millard</surname><given-names>M</given-names></name><name><surname>Wakabi</surname><given-names>S</given-names></name><name><surname>Lukwago</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><issue>8</issue><fpage>905</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70152-0</pub-id><?supplied-pmid 25910637?><pub-id pub-id-type="pmid">25910637</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015;15(8):905&#x02013;12.<pub-id pub-id-type="pmid">25910637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Godwin</surname><given-names>CL</given-names></name><name><surname>Wohl</surname><given-names>DA</given-names></name><name><surname>Fischer Nd</surname><given-names>WA</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Hawks</surname><given-names>DA</given-names></name><name><surname>Devore</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Reproductive health sequelae among women who survived Ebola virus disease in Liberia</article-title><source>Int J Gynaecol Obstet</source><year>2019</year><volume>146</volume><issue>2</issue><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1002/ijgo.12858</pub-id><?supplied-pmid 31074837?><pub-id pub-id-type="pmid">31074837</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Godwin CL, Wohl DA, Fischer Nd WA, Singh K, Hawks DA, Devore EE, et al. Reproductive health sequelae among women who survived Ebola virus disease in Liberia. Int J Gynaecol Obstet. 2019;146(2):212&#x02013;7.<pub-id pub-id-type="pmid">31074837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>PJ</given-names></name><name><surname>Walder</surname><given-names>AR</given-names></name><name><surname>Lisk</surname><given-names>DR</given-names></name><name><surname>Fitzgerald</surname><given-names>F</given-names></name><name><surname>Sevalie</surname><given-names>S</given-names></name><name><surname>Lado</surname><given-names>M</given-names></name><etal/></person-group><article-title>Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic</article-title><source>Sierra Leone Emerg Infect Dis</source><year>2018</year><volume>24</volume><issue>8</issue><fpage>1412</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.3201/eid2408.171367</pub-id><?supplied-pmid 30014839?><pub-id pub-id-type="pmid">30014839</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Howlett PJ, Walder AR, Lisk DR, Fitzgerald F, Sevalie S, Lado M, et al. Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic. Sierra Leone Emerg Infect Dis. 2018;24(8):1412&#x02013;21.<pub-id pub-id-type="pmid">30014839</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Ryn</surname><given-names>CV</given-names></name><name><surname>Badio</surname><given-names>M</given-names></name><name><surname>Fayiah</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Gayedyu-Dennis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical Sequelae Among Individuals With Pauci-Symptomatic or Asymptomatic Ebola Virus Infection and Unrecognised Ebola Virus Disease in Liberia: A Longitudinal Cohort Study</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><issue>8</issue><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00127-X</pub-id><?supplied-pmid 35588755?><pub-id pub-id-type="pmid">35588755</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kelly JD, Ryn CV, Badio M, Fayiah T, Johnson K, Gayedyu-Dennis D, et al. Clinical Sequelae Among Individuals With Pauci-Symptomatic or Asymptomatic Ebola Virus Infection and Unrecognised Ebola Virus Disease in Liberia: A Longitudinal Cohort Study. Lancet Infect Dis. 2022;22(8):1163&#x02013;71.<pub-id pub-id-type="pmid">35588755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Fletcher</surname><given-names>TE</given-names></name><name><surname>Adhikari</surname><given-names>NKJ</given-names></name><name><surname>Portella</surname><given-names>G</given-names></name><etal/></person-group><article-title>Ebola virus disease and critical illness</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>217</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1325-2</pub-id><?supplied-pmid 27468829?><pub-id pub-id-type="pmid">27468829</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Leligdowicz A, Fischer WA, Uyeki TM, Fletcher TE, Adhikari NKJ, Portella G, et al. Ebola virus disease and critical illness. Crit Care. 2016;20(1):217.<pub-id pub-id-type="pmid">27468829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Bah</surname><given-names>AJ</given-names></name><name><surname>James</surname><given-names>PB</given-names></name><name><surname>Bah</surname><given-names>N</given-names></name><name><surname>Sesay</surname><given-names>AB</given-names></name><name><surname>Sevalie</surname><given-names>S</given-names></name><name><surname>Kanu</surname><given-names>JS</given-names></name></person-group><article-title>Prevalence of anxiety, depression and post-traumatic stress disorder among Ebola survivors in northern Sierra Leone: a cross-sectional study</article-title><source>BMC Public Health</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>1391</fpage><pub-id pub-id-type="doi">10.1186/s12889-020-09507-6</pub-id><?supplied-pmid 32917162?><pub-id pub-id-type="pmid">32917162</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bah AJ, James PB, Bah N, Sesay AB, Sevalie S, Kanu JS. Prevalence of anxiety, depression and post-traumatic stress disorder among Ebola survivors in northern Sierra Leone: a cross-sectional study. BMC Public Health. 2020;20(1):1391.<pub-id pub-id-type="pmid">32917162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawry</surname><given-names>LL</given-names></name><name><surname>Stroupe Kannappan</surname><given-names>N</given-names></name><name><surname>Canteli</surname><given-names>C</given-names></name><name><surname>Clemmer</surname><given-names>W</given-names></name></person-group><article-title>Mixed-methods assessment of health and mental health characteristics and barriers to healthcare for Ebola survivors in Beni, Butembo and Katwa health zones of the Democratic Republic of Congo</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><issue>8</issue><fpage>e050349</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-050349</pub-id><?supplied-pmid 34380729?><pub-id pub-id-type="pmid">34380729</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lawry LL, Stroupe Kannappan N, Canteli C, Clemmer W. Mixed-methods assessment of health and mental health characteristics and barriers to healthcare for Ebola survivors in Beni, Butembo and Katwa health zones of the Democratic Republic of Congo. BMJ Open. 2021;11(8): e050349.<pub-id pub-id-type="pmid">34380729</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Shantha</surname><given-names>JG</given-names></name><name><surname>Crozier</surname><given-names>I</given-names></name><name><surname>Yeh</surname><given-names>S</given-names></name></person-group><article-title>An update on ocular complications of Ebola virus disease</article-title><source>J Curr Ophthalmol</source><year>2017</year><volume>28</volume><issue>6</issue><fpage>600</fpage><lpage>606</lpage></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Shantha JG, Crozier I, Yeh S. An update on ocular complications of Ebola virus disease. J Curr Ophthalmol. 2017;28(6):600&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedemann</surname><given-names>A</given-names></name><name><surname>Foucat</surname><given-names>E</given-names></name><name><surname>Hocini</surname><given-names>H</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Hejblum</surname><given-names>BP</given-names></name><name><surname>Durand</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-lasting severe immune dysfunction in Ebola virus disease survivors</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>3730</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17489-7</pub-id><?supplied-pmid 32709840?><pub-id pub-id-type="pmid">32709840</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum BP, Durand M, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.<pub-id pub-id-type="pmid">32709840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Bwire</surname><given-names>G</given-names></name><name><surname>Sartorius</surname><given-names>B</given-names></name><name><surname>Guerin</surname><given-names>P</given-names></name><name><surname>Tegegne</surname><given-names>MA</given-names></name><name><surname>Okware</surname><given-names>SI</given-names></name><name><surname>Talisuna</surname><given-names>AO</given-names></name></person-group><article-title>Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-02847-1</pub-id><?supplied-pmid 37055861?><pub-id pub-id-type="pmid">37055861</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Bwire G, Sartorius B, Guerin P, Tegegne MA, Okware SI, Talisuna AO. Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa. BMC Med. 2023;21(1):144.<pub-id pub-id-type="pmid">37055861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Glynn M, Drake WM. Hutchison's clinical methods: An integrated approach to clinical practice. 25th ed:&#x000a0;London: Elsevier; 2022;9780323775847.</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>Y</given-names></name><name><surname>Fornace</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Arnold</surname><given-names>BF</given-names></name><name><surname>Priest</surname><given-names>JW</given-names></name><name><surname>Martin</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Determining seropositivity-A review of approaches to define population seroprevalence when using multiplex bead assays to assess burden of tropical diseases</article-title><source>PLoS Negl Trop Dis</source><year>2021</year><volume>15</volume><issue>6</issue><fpage>e0009457</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0009457</pub-id><?supplied-pmid 34181665?><pub-id pub-id-type="pmid">34181665</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chan Y, Fornace K, Wu L, Arnold BF, Priest JW, Martin DL, et al. Determining seropositivity-A review of approaches to define population seroprevalence when using multiplex bead assays to assess burden of tropical diseases. PLoS Negl Trop Dis. 2021;15(6): e0009457.<pub-id pub-id-type="pmid">34181665</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Wohl</surname><given-names>DA</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names></name><name><surname>Mei</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Tozay</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>E</given-names></name><etal/></person-group><article-title>Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long Ebola</article-title><source>Clin Infect Diseases</source><year>2023</year><volume>76</volume><issue>3</issue><fpage>e835</fpage><lpage>e840</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac732</pub-id><pub-id pub-id-type="pmid">36065768</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wohl DA, Fischer WA, Mei W, Zou F, Tozay S, Reeves E, et al. Post-Ebola Symptoms 7 Years After Infection: The Natural History of Long Ebola. Clin Infect Diseases. 2023;76(3):e835&#x02013;40.<pub-id pub-id-type="pmid">36065768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>NG</given-names></name><name><surname>Grant</surname><given-names>DS</given-names></name><name><surname>Himmelfarb</surname><given-names>ST</given-names></name><name><surname>Engel</surname><given-names>EJ</given-names></name><name><surname>Al-Hasan</surname><given-names>F</given-names></name><name><surname>Gbakie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone</article-title><source>Clin Infect Diseases</source><year>2021</year><volume>73</volume><issue>6</issue><fpage>1046</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab267</pub-id><pub-id pub-id-type="pmid">33822010</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Bond NG, Grant DS, Himmelfarb ST, Engel EJ, Al-Hasan F, Gbakie M, et al. Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone. Clin Infect Diseases. 2021;73(6):1046&#x02013;54.<pub-id pub-id-type="pmid">33822010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname><given-names>P</given-names></name><name><surname>Kaiser</surname><given-names>L</given-names></name><name><surname>Schibler</surname><given-names>M</given-names></name><name><surname>Ciglenecki</surname><given-names>I</given-names></name><name><surname>Bausch</surname><given-names>DG</given-names></name></person-group><article-title>Sequelae of Ebola virus disease: the emergency within the emergency</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><issue>6</issue><fpage>e82</fpage><lpage>e91</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)00077-3</pub-id><?supplied-pmid 27020309?><pub-id pub-id-type="pmid">27020309</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016;16(6):e82&#x02013;91.<pub-id pub-id-type="pmid">27020309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AI</given-names></name><name><surname>Chughtai</surname><given-names>M</given-names></name><name><surname>Loua</surname><given-names>TO</given-names></name><name><surname>Pe Kolie</surname><given-names>J</given-names></name><name><surname>Camara</surname><given-names>HF</given-names></name><name><surname>Ishfaq</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Study of Ebola Virus Disease Survivors in Guinea</article-title><source>Clin Infect Diseases</source><year>2015</year><volume>61</volume><issue>7</issue><fpage>1035</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1093/cid/civ453</pub-id><pub-id pub-id-type="pmid">26060289</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Qureshi AI, Chughtai M, Loua TO, Pe Kolie J, Camara HF, Ishfaq MF, et al. Study of Ebola Virus Disease Survivors in Guinea. Clin Infect Diseases. 2015;61(7):1035&#x02013;42.<pub-id pub-id-type="pmid">26060289</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>AK</given-names></name><name><surname>Bertolli</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>AS</given-names></name><name><surname>Mukunu</surname><given-names>R</given-names></name><name><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name><name><surname>Bressler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epid&#x000e9;mies &#x000e0; Kikwit</article-title><source>J Infect Dis.</source><year>1999</year><volume>179 Suppl 1</volume><fpage>S28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1086/514318</pub-id><?supplied-pmid 9988162?><pub-id pub-id-type="pmid">9988162</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epid&#x000e9;mies &#x000e0; Kikwit. J Infect Dis. 1999;179 Suppl 1:S28-35.<pub-id pub-id-type="pmid">9988162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Billioux</surname><given-names>BJ</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Neurological Complications of Ebola Virus Infection</article-title><source>Neurotherapeutics</source><year>2016</year><volume>13</volume><issue>3</issue><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1007/s13311-016-0457-z</pub-id><?supplied-pmid 27412684?><pub-id pub-id-type="pmid">27412684</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Billioux BJ, Smith B, Nath A. Neurological Complications of Ebola Virus Infection. Neurotherapeutics. 2016;13(3):461&#x02013;70.<pub-id pub-id-type="pmid">27412684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><collab>The PREVAIL III Study Group</collab></person-group><article-title>A Longitudinal Study of Ebola Sequelae in Liberia</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>10</issue><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805435</pub-id><pub-id pub-id-type="pmid">30855742</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">The PREVAIL III Study Group. A Longitudinal Study of Ebola Sequelae in Liberia. N Engl J Med. 2019;380(10):924&#x02013;34.<pub-id pub-id-type="pmid">30855742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Mandizadza</surname><given-names>OO</given-names></name><name><surname>Phebeni</surname><given-names>RT</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name></person-group><article-title>Prevalence of somatic symptoms among Ebola Virus Disease (EVD) survivors in Africa: a systematic review and meta-analysis</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>1511</fpage><pub-id pub-id-type="doi">10.1186/s12889-024-19013-8</pub-id><?supplied-pmid 38840082?><pub-id pub-id-type="pmid">38840082</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Mandizadza OO, Phebeni RT, Ji C. Prevalence of somatic symptoms among Ebola Virus Disease (EVD) survivors in Africa: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):1511.<pub-id pub-id-type="pmid">38840082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Varkey</surname><given-names>JB</given-names></name><name><surname>Shantha</surname><given-names>JG</given-names></name><name><surname>Crozier</surname><given-names>I</given-names></name><name><surname>Kraft</surname><given-names>CS</given-names></name><name><surname>Lyon</surname><given-names>GM</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Persistence of Ebola Virus in Ocular Fluid during Convalescence</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>25</issue><fpage>2423</fpage><lpage>2427</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500306</pub-id><?supplied-pmid 25950269?><pub-id pub-id-type="pmid">25950269</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med. 2015;372(25):2423&#x02013;7.<pub-id pub-id-type="pmid">25950269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Velazquez</surname><given-names>JV</given-names></name><name><surname>Bond</surname><given-names>NG</given-names></name><name><surname>Schieffelin</surname><given-names>JS</given-names></name><name><surname>Gunn</surname><given-names>BM</given-names></name></person-group><article-title>Survivors of Ebola virus disease exhibit elevated levels of autoantibodies</article-title><source>J Immunol.</source><year>2023</year><volume>210</volume><issue>1_Supplement</issue><fpage>59.27</fpage><lpage>59.27</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.210.Supp.59.27</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Velazquez JV, Bond NG, Schieffelin JS, Gunn BM. Survivors of Ebola virus disease exhibit elevated levels of autoantibodies. J Immunol. 2023;210(1_Supplement):59.27-59.27.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ebola virus sequesters IRF3 in viral inclusion bodies to evade host antiviral immunity</article-title><source>eLife.</source><year>2024</year><volume>12</volume><fpage>RP88122</fpage><pub-id pub-id-type="doi">10.7554/eLife.88122.3</pub-id><?supplied-pmid 38285487?><pub-id pub-id-type="pmid">38285487</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhu L, Jin J, Wang T, Hu Y, Liu H, Gao T, et al. Ebola virus sequesters IRF3 in viral inclusion bodies to evade host antiviral immunity. eLife. 2024;12:RP88122.<pub-id pub-id-type="pmid">38285487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Hartley C, Bavinger JC, Kuthyar S, Shantha JG, Yeh S. Pathogenesis of Uveitis in Ebola Virus Disease Survivors: Evolving Understanding from Outbreaks to Animal Models. Microorganisms. 2020;8(4):594.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Subtil</surname><given-names>F</given-names></name><name><surname>Delaunay</surname><given-names>C</given-names></name><name><surname>Keita</surname><given-names>AK</given-names></name><name><surname>Sow</surname><given-names>MS</given-names></name><name><surname>Tour&#x000e9;</surname><given-names>A</given-names></name><name><surname>Leroy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea</article-title><source>Clin Infect Diseases</source><year>2017</year><volume>64</volume><issue>12</issue><fpage>1788</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1093/cid/cix210</pub-id><pub-id pub-id-type="pmid">28329169</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Subtil F, Delaunay C, Keita AK, Sow MS, Tour&#x000e9; A, Leroy S, et al. Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clin Infect Diseases. 2017;64(12):1788&#x02013;90.<pub-id pub-id-type="pmid">28329169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Deen</surname><given-names>GF</given-names></name><name><surname>Broutet</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Knust</surname><given-names>B</given-names></name><name><surname>Sesay</surname><given-names>FR</given-names></name><name><surname>McDonald</surname><given-names>SLR</given-names></name><etal/></person-group><article-title>Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>15</issue><fpage>1428</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1511410</pub-id><?supplied-pmid 26465681?><pub-id pub-id-type="pmid">26465681</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Deen GF, Broutet N, Xu W, Knust B, Sesay FR, McDonald SLR, et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report. N Engl J Med. 2017;377(15):1428&#x02013;37.<pub-id pub-id-type="pmid">26465681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Mate</surname><given-names>SE</given-names></name><name><surname>Kugelman</surname><given-names>JR</given-names></name><name><surname>Nyenswah</surname><given-names>TG</given-names></name><name><surname>Ladner</surname><given-names>JT</given-names></name><name><surname>Wiley</surname><given-names>MR</given-names></name><name><surname>Cordier-Lassalle</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular Evidence of Sexual Transmission of Ebola Virus</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>25</issue><fpage>2448</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1509773</pub-id><?supplied-pmid 26465384?><pub-id pub-id-type="pmid">26465384</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, et al. Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med. 2015;373(25):2448&#x02013;54.<pub-id pub-id-type="pmid">26465384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of sexual transmission on the West Africa Ebola outbreak in 2014: a mathematical modelling study</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>1653</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-38397-3</pub-id><?supplied-pmid 30733561?><pub-id pub-id-type="pmid">30733561</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Luo D, Zheng R, Wang D, Zhang X, Yin Y, Wang K, et al. Effect of sexual transmission on the West Africa Ebola outbreak in 2014: a mathematical modelling study. Sci Rep. 2019;9(1):1653.<pub-id pub-id-type="pmid">30733561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Surani</surname><given-names>A</given-names></name><name><surname>Marfatia</surname><given-names>YS</given-names></name><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name></person-group><article-title>Ebola virus: An emerging sexually transmissible infection pathogen</article-title><source>Indian J Sex Transm Dis AIDS</source><year>2018</year><volume>39</volume><issue>1</issue><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.4103/ijstd.IJSTD_21_18</pub-id><?supplied-pmid 30187032?><pub-id pub-id-type="pmid">30187032</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Surani A, Marfatia YS, Pal A, Shah R. Ebola virus: An emerging sexually transmissible infection pathogen. Indian J Sex Transm Dis AIDS. 2018;39(1):65&#x02013;7.<pub-id pub-id-type="pmid">30187032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname><given-names>P</given-names></name><name><surname>Fischer</surname><given-names>WA</given-names><suffix>II</suffix></name><name><surname>Schibler</surname><given-names>M</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><name><surname>Bausch</surname><given-names>DG</given-names></name><name><surname>Kaiser</surname><given-names>L</given-names></name></person-group><article-title>Ebola Virus Shedding and Transmission: Review of Current Evidence</article-title><source>J Infect Dis.</source><year>2016</year><volume>214</volume><issue>suppl_3</issue><fpage>S177</fpage><lpage>S84</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw254</pub-id><?supplied-pmid 27443613?><pub-id pub-id-type="pmid">27443613</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Vetter P, Fischer WA II, Schibler M, Jacobs M, Bausch DG, Kaiser L. Ebola Virus Shedding and Transmission: Review of Current Evidence. J Infect Dis. 2016;214(suppl_3):S177&#x02013;84.<pub-id pub-id-type="pmid">27443613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Riesle-Sbarbaro</surname><given-names>SA</given-names></name><name><surname>Wibbelt</surname><given-names>G</given-names></name><name><surname>D&#x000fc;x</surname><given-names>A</given-names></name><name><surname>Kouakou</surname><given-names>V</given-names></name><name><surname>Bokelmann</surname><given-names>M</given-names></name><name><surname>Hansen-Kant</surname><given-names>K</given-names></name><etal/></person-group><article-title>Selective replication and vertical transmission of Ebola virus in experimentally infected Angolan free-tailed bats</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>925</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-45231-0</pub-id><?supplied-pmid 38297087?><pub-id pub-id-type="pmid">38297087</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Riesle-Sbarbaro SA, Wibbelt G, D&#x000fc;x A, Kouakou V, Bokelmann M, Hansen-Kant K, et al. Selective replication and vertical transmission of Ebola virus in experimentally infected Angolan free-tailed bats. Nat Commun. 2024;15(1):925.<pub-id pub-id-type="pmid">38297087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease. Geneva: World Health Organization; 2020. ISBN-13: 978-92-4-000138-1.</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">de St. Maurice A, Ervin E, Orone R, Choi M, Dokubo EK, Rollin PE, et al. Care of Ebola Survivors and Factors Associated With Clinical Sequelae&#x02014;Monrovia, Liberia. Open Forum Infect Dis. 2018;5(10):239.</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Henwood</surname><given-names>PC</given-names></name><name><surname>Bebell</surname><given-names>LM</given-names></name><name><surname>Roshania</surname><given-names>R</given-names></name><name><surname>Wolfman</surname><given-names>V</given-names></name><name><surname>Mallow</surname><given-names>M</given-names></name><name><surname>Kalyanpur</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ebola Virus Disease and Pregnancy: A Retrospective Cohort Study of Patients Managed at 5 Ebola Treatment Units in West Africa</article-title><source>Clin Infect Diseases</source><year>2017</year><volume>65</volume><issue>2</issue><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1093/cid/cix290</pub-id><pub-id pub-id-type="pmid">28379374</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Henwood PC, Bebell LM, Roshania R, Wolfman V, Mallow M, Kalyanpur A, et al. Ebola Virus Disease and Pregnancy: A Retrospective Cohort Study of Patients Managed at 5 Ebola Treatment Units in West Africa. Clin Infect Diseases. 2017;65(2):292&#x02013;9.<pub-id pub-id-type="pmid">28379374</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>